Deal Snapshot
US MERCK TO ACQUIRE DRUGMAKER TILOS THERAPEUTICS
Tuesday 11 June 2019

US-based pharmaceutical company Merck (NYSE: MRK) has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFb complex for the treatment of cancer, fibrosis and autoimmune diseases, the company said.
Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Tilos for total potential consideration of up to USD 773m, including an upfront payment as well as contingent milestone payments.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 11/06/2019
Target: Tilos Therapeutics
Country: USA
Deal Size: 773m (USD)
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing: Cash
Status: Agreed
Vendor:
Buyer: Merck
Comment:


Options